Application of surface-enhanced optical spectroscopy for the analysis of organic compounds in cerebrospinal fluid samples

Duration of the project

01.03.2025. - 31.10.2025.

Countries and institutions involved in the project

flag-LT
Vilnius University
flag-DE
Dresden University of Technology

Project manager

Prof. Dr. Justinas Čeponkus

Aim(s) of the project

The objective of the project is to analyze CSF samples obtained from e.g. the ventricular system or the spinal canal using surface enhanced spectroscopic methods. The main focus of the spectroscopic analysis will be on organic compounds such as proteins, carbohydrates and their derivatives. In this way, previously only suspected indicators for a sensitive evaluation of pathological processes can be described in more detail for the first time. To date, any routine clinical method can only poorly differentiate these compounds and require a prolonged time up to 24h. The unique possibilities of surface enhanced spectroscopy with regard to an increased local concentration and the intrinsic amplification effect could provide access to the desired molecular information and – as an optically based method – might allow immediate read out of the information, therefore, paving the way for an on site technology.

Public events

A workshop will take place at the TU Dresden, Campus Chemnitz. Open to public. Here, the samples will be handed over and mutual reports on the status of the work will be given. Date: 2-4 June 2025.

  • Speaker: Prof. Dr. Matthias Kirsch (DE), Prof. Dr. Justinas Čeponkus (LT), NN (GE)

 

The second public workshop will serve to conclude the project and will be in Vilnius. Date 6-8 October 2025. The results achieved will be evaluated jointly. If the results are positive, a joint publication will be planned.

  • Speaker: project leader: Prof. Dr. Justinas Čeponkus (LT), Prof. Dr. Matthias Kirsch (DE), Prof. Dr. Gerald Steiner (GE), NN (GE)

Direct and indirect target group of the project

Direct:  The direct target group of the project are patients with diseases associated with pathological changes in the spinal canal – 50 to 60 people per year.

 

Indirect:  Indirect targets are also patients with other diseases, especially neurological diseases. Expected number of people – 50 to 60 people per year.